Rebirthel Co.,Ltd. is an independent biocompany based in Kyoto, Japan that is focused on the development of cellular immunotherapies for cancer. The company, founded in 2019, aims to realize cell-based therapies against cancer and other immune-related diseases by utilizing universal T cells regenerated from pluripotent stem cells. This innovative strategy is based on methods developed by Dr. Hiroshi Kawamoto of Kyoto University. Their latest achievement includes a Venture Round investment at 01 December 2022 led by Healthcare Innovation. Rebirthel operates within the realms of Biotechnology, Health Care, Health and Wellness, and Life Sciences.
No recent news or press coverage available for Rebirthel Co.,Ltd..